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Human pluripotent stem cells (hPSCs) are adhesion-dependent cells that require 29 
cultivation in colonies to maintain growth and pluripotency. Robust differentiation protocols 30 
necessitate single cell cultures that are achieved by use of ROCK (Rho kinase) inhibitors. 31 
ROCK inhibition enables maintenance of stem cell phenotype; its effects on metabolism are 32 
unknown. hPSCs were exposed to 10μM ROCK inhibitor for varying exposure times. 33 
Pluripotency (TRA-1-81, SSEA3, OCT4, NANOG, SOX2) remained unaffected, until after 34 
prolonged exposure (96 hrs). Gas chromatography–mass spectrometry metabolomics analysis 35 
identified differences between ROCK-treated and untreated cells as early as 12 hrs. Exposure 36 
for 48 hours resulted in reduction in glycolysis, glutaminolysis, the citric acid (TCA) cycle as 37 
well as the amino acids pools, suggesting the adaptation of the cells to the new culture 38 
conditions, which was also reflected by the expression of the metabolic regulators, mTORC1 39 
and tp53 and correlated with cellular proliferation status. While gene expression and protein 40 
levels did not reveal any changes in the physiology of the cells, metabolomics revealed the 41 
fluctuating state of the metabolism. The above highlight the usefulness of metabolomics in 42 
providing accurate and sensitive information on cellular physiological status, which could lead 43 
to the development of robust and optimal stem cell bioprocesses.  44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
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Introduction 53 
Human pluripotent stem cells have the ability to self-renew and differentiate to any cell 54 
type of the body, which renders them important to both research and potential regenerative 55 
medicine therapeutic applications 1. hPSCs, both embryonic and induced pluripotent, are 56 
optimally maintained in colonies yet efficient and robust differentiation protocols are best 57 
achieved by single cell cultures 2. Addressing challenges of directed differentiation in vitro, 58 
such as scaling-up of the cultures, elimination of xeno-components, efficiency, etc., as well as 59 
understanding the epigenetic differences on methylation patterns between hESCs and hiPSCs 60 
3, requires precise and sensitive monitoring of cell cultures that provides insightful information 61 
on cellular state.  62 
Metabolism is the set of life-sustaining chemical transformations within the cells that 63 
is considered as the most dynamic. It directly reacts with the environment and provides fast 64 
response to environmental perturbations. Metabolism is simultaneously both autonomous and 65 
inter-connected with the other levels of the cellular function, such as protein and gene 66 
expression as well epigenetic changes. Emerging evidence suggests that pluripotent stem cells 67 
are metabolically distinct from their differentiated counterparts and that these metabolic 68 
properties are important for stem cell identity. Furthermore, molecular regulators of energy 69 
metabolism have essential roles in stem cell fate, in particular, the decision to self-renew or 70 
differentiate and stem cells respond to fluctuations in energy states in vivo 4. Specifically, 71 
metabolic activity and metabolite pools affect stem cell epigenetic mechanisms in a direct way 72 
5 influencing stem cell differentiation potential 6-8. It is of great importance to define cell state 73 
- undifferentiated or differentiated - by its metabolic properties as this is in direct correlation 74 
with the cells’ potential.   75 
Single cell cultures in suspension of hPSCs undergo apoptosis despite the use of culture 76 
conditions conducive to stem cell maintenance 9,10. This problem has been addressed with the 77 
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inhibition of ROCK (Rho-associated protein kinase), a serine-threonine kinase that 78 
phosphorylates and activates the myosin II pathway 11-16 resulting in the maintenance of the 79 
differentiation potential for up to 72 hours, which is considered to be primarily mediated via 80 
the inhibition of an E-cadherin-dependent apoptotic pathway 17-20. The most effective ROCK 81 
inhibitor is Y-27632 21. hPSCs colonies, both hESCs and hiPSCs, are most commonly treated 82 
with 10μM of Y-27632 prior to dissociation of the colonies into single cells 22-24. With this 83 
protocol, single cell survival is maintained for up to 3 weeks and stem cell phenotype along 84 
with differentiation capability into all lineages are sustained 11. Until now, it has been assumed 85 
that ROCK inhibition does not affect physiology since the hPSCs retain their stemness and 86 
survive 25.  87 
Herein, we have undertaken an in-depth assessment of the effect of ROCK inhibitor 88 
(Y-27632) on the dynamic metabolism of hPSCs over a 96-hour culture period 26-28. Whereas 89 
no differences were observed in the pluripotency and viability of hESCs and hiPSCs on gene 90 
and protein expression levels, differences in metabolism were detected. Specifically, 91 
metabolomics analysis was able to detect changes on the metabolic physiology of the cells as 92 
early as 12h of ROCK inhibitor treatment. Existing metabolic switches on hESCs and hiPSCs 93 
were similar on both cell types up to 48h of exposure to Y-27632, with 24h exposure being 94 
identified to be critical as a turning point in metabolism. Correlating with these metabolic 95 
changes, a differential expression of the metabolic regulators, p53 29,30 and mTORC1 4,31, was 96 
observed. The above indicate a dynamic process of adaptation of the cells to the altered 97 
environment, which is mostly projected to the metabolic level. 98 
  99 
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Results 100 
 101 
hPSCs maintain pluripotency phenotype up to 48h of exposure to ROCK inhibitor 102 
The effects of Y-27632 exposure on both hESCs and hiPSCs were evaluated by 103 
assessing gene and protein expression of pluripotency markers. Specifically, TRA-1-81 and 104 
SSEA3 expression indicated that the cells retained these pluripotency markers up to 48h of 105 
exposure, whereas there was a reduction at 96h in both cell types (p < 0.05; Figure 1b). 106 
Intracellular expression of Nanog, Oct4 and Sox2 indicated maintenance of stemness at high 107 
levels (over 67% for hESCs and 80% for hiPSCs), which is reduced at 96h exposure for hESCs 108 
(p < 0.05; Figure 1b). Nanog, Oct4 and Sox2 expression did not differ at any time-point 109 
evaluated (data not shown). Consequently, gene and protein expression showed that the 110 
pluripotency phenotype remained constant for at least 48 hours after ROCK exposure and was 111 
similar to the untreated control. In all cases, cell viability was high (data not shown). 112 
Immunostaining for Oct4 and Sox2 confirmed the maintenance of pluripotency, apart from the 113 
96h time-point in hESCs when the staining appeared to be weaker (Supplementary Figure 1), 114 
in agreement with the flow cytometry results (Figure 1b). 115 
 116 
Metabolomics analysis reveals changes in metabolism  117 
Multivariate statistical analysis revealed that 0h–untreated cells (grown in colonies and 118 
not exposed to Y-27632) had discrete metabolism compared to those exposed to Y-27632 as 119 
early as 12hrs, as highlighted by HCL analyses and heatmaps (Figure 2b). Grouping of the 120 
metabolic profiles from cells exposed 48h and 96h to ROCK inhibitor demonstrated that 121 
prolonged exposure resulted in adapted cellular physiology not as discrete as that of cells 122 
exposed for 12h and 24h, as elucidated by the grouping in PCA graphs (Figure 2a). Alas, the 123 
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distinct grouping of the hESCs and hiPSCs at 12h exposure indicates a different physiological 124 
response of the cells (Figure 2a).  125 
To further understand how cellular physiology changed with culture time, an in-depth 126 
assessment of the metabolic transitions was undertaken: consecutively from 0h to 12h, 12h to 127 
24h, 24h to 48h and 48h to 96h by SAM (Figure 3). At 12 hours of Y-27632 exposure, the 128 
metabolic profiles were similar for both hESCs and hiPSCs; glucose concentration increased 129 
whereas lactate and alanine production decreased, indicating down-regulation of the glycolytic 130 
route. TCA cycle and glutaminolysis were also down-regulated. Some amino acids (glycine, 131 
proline, and GABA for both ESCs and iPSCs, and threonine, serine, phenylalanine, tyrosine 132 
for hESCs) and urea (for both cell types) were reduced. From 12h to 24h, the most important 133 
difference was the reduction of metabolites in the serine-glycine-threonine pathway. In 134 
addition, aspartate was reduced in both hiPSCs and hESCs. The further reduction at 24h in the 135 
metabolite pools is more intense in hiPSCs. After 48h of exposure time, metabolism increased 136 
as indicated by the activation of glycolysis, glutaminolysis, TCA cycle and amino acid pools 137 
(serine, glycine, threonine for both types of cells, ornithine, phenylalanine for hESCs, and 138 
aspartate, leucine, valine for hiPSCs). Overall, the metabolic behaviour of hESCs and hiPSCs 139 
was similar up to 48h. In contrast, at 96h only hESCs increased glycolytic rate and up-regulated 140 
the TCA cycle with increased aspartate whereas hiPSCs down-regulated glutaminolysis and 141 
aspartate production. Hence, not only was the metabolism of ROCK-exposed hPSCs different 142 
from that of the day 0 control, but cells sequentially down-regulated metabolism at 12 and 24 143 
hours, followed by an upregulated metabolic profile at 48 hours and had completely disparate 144 
physiology by 96 hours of exposure. 145 
 146 
Caspase-3 expression did not differ up to 48 hours of ROCK exposure. 147 
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ROCK inhibition blocks caspase-3 apoptotic signalling 32,33. qRT-PCR analysis 148 
confirmed that there was no change in caspase-3 expression at any time-point in the hiPSCs 149 
cultures (data not shown). In contrast, there was a significant decrease in caspase-3 expression 150 
in hESCs from 48h to 96h of ROCK inhibition (Figure 4a). This alteration of caspase-3 from 151 
48h to 96h may reflect on the increased activity of metabolic pathways such as glycolysis, TCA 152 
cycle, glycerolipids and phospholipids synthesis in hESCs, which is required for apoptosis 34, 153 
as shown in Figure 4b, after significant analysis and comparison of the metabolic profiles of 154 
the two time-points. Regardless, changes in metabolism observed throughout in the cultures of 155 
both hPSC types cannot be explained by changes in caspase-3 expression, which remained 156 
stable for at least 48 hours and similar to that of 0h control unexposed cells. In all cases, the 157 
viability of the cells remained high (data not shown). 158 
 159 
mTORC1 expression correlated with metabolic changes, independent of tp53. 160 
Expression of two major metabolic controllers, mTORC1 and tp53, was assessed. In 161 
hESC cultures inhibited by ROCK (Figure 5), no difference in tp53 expression throughout the 162 
culture time was observed. In contrast, mTORC1 expression was lower at 24h and 96h exposure 163 
compared to the control 0h unexposed cells (p < 0.05; Figure 5a), correlating with decreased 164 
metabolic activity at the same time points (Figure 5b), as identified by the significant analysis 165 
of the metabolic profiles between these time-points. Specifically, at 24h glycolysis and 166 
glutaminolysis, lipid synthesis, most of the amino acid pools and TCA cycle were less active, 167 
whereas at 96h glycolysis and glutaminolysis were reduced compared to the control 0h 168 
unexposed group. In hiPSC cultures inhibited by ROCK (Figure 6), expression of tp53 was 169 
higher only at 96h exposure compared with that at 24h exposure, coincident with the increased 170 
glycolysis and glutaminolysis, TCA cycle and lipid synthesis at 96h exposure (Figures 6a & 171 
6b). In contrast, mTORC1 expression was lower following 24h exposure and then increased 172 
8 
 
again at 96h exposure (p < 0.05), correlating with similar changes in metabolism. Therefore, 173 
in both hESCs and hiPSCs, decreased expression of mTORC1 correlated with reduced 174 
metabolism after 24h of exposure with Y-27632, independent of tp53 and caspase3 expression 175 
levels.  176 
 177 
ROS/RNS levels and catalase expression suggest a correlation with proliferative 178 
metabolism 179 
The measurement of reactive oxygen and nitrogen species (ROS/RNS) indicated a 180 
reduction in ROCK inhibitor-treated hESCs throughout the culture period. In contrast, 181 
following an initial reduction of ROS/RNS at 12h and 48h, an increase in ROS/RNS was 182 
observed at 96h in hiPSCs (Supplementary Figure 2). Catalase expression was also 183 
significantly increased at 96h in hiPSCs cultures compared to 12h, 24h and 48h. No significant 184 
change has been observed in glutamylcysteine synthetase (GCS) expression in both hESC and 185 
hiPSC cultures whereas a significant decrease of glutathione peroxidase 1 (GPX-1) expression 186 
was observed only at 24h in hESCs (Supplementary Figure 3).  187 
 188 
  189 
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Discussion 190 
The use of the ROCK inhibitor on hPSCs has been shown not to affect their stemness 191 
18,25. In contrast, its effect on metabolism has not been investigated. Herein, we confirm that 192 
treatment of hiPSCs and hESCs with ROCK inhibitor does not affect the expression of 193 
pluripotency markers at gene and protein level, whereas their metabolism is altered and 194 
becomes distinctly different. The observed metabolic changes appeared to be irreversible since 195 
the cells did not revert back to the metabolic signature of untreated cells. Furthermore, the 196 
metabolic transitions, in both cell types, were similar up to 48h of ROCK inhibitor exposure 197 
and correlated with expression levels of mTORC1 at 24h of ROCK inhibition, but were 198 
independent of tp53 or caspase-3 expression. Finally, the detected metabolic differences 199 
between hESCs and hiPSCs indicate that although the two hPSC types share many phenotypic 200 
similarities, they are not physiologically identical suggesting that their metabolic features 201 
should be considered in designing hPSC bioprocesses to deliver robust maintenance and 202 
differentiation protocols. 203 
The effects on metabolism could be explained by the single cell culture conditions that 204 
result in loss of cell-to-cell contact, changes to nutrient availability in single cell cultures 205 
compared to that for cells grown within colonies, and the time-period required for cells to adapt 206 
to an environment conducive to single cell culture. hPSCs are highly proliferative cells and 207 
share metabolic characteristics with cancer cells 26-28. In tumors, the glycolytic rate is reduced 208 
when E-cadherin is unbound 35 similar to what we observed when the 0h-untreated cells 209 
cultured in colonies were compared with treated cells at other time-points. After 12h and 24h 210 
of exposure to ROCK inhibitor, the metabolism of both hESCs and hiPSCs was down-211 
regulated, less glycolytic and, therefore, less proliferative. According to literature on 212 
mammalian signalling, an indirect connection between ROCK and mTORC1 exists. ROCK 213 
inhibition has been shown to dramatically suppress phosphorylation and activity of FAK (Focal 214 
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Adhesion Kinase) 36, 37. FAK activation has also been correlated with increased proliferation 215 
via regulation of the Akt/mTORC1 pathway 38. Recently, this relationship was demonstrated 216 
at the metabolic level, where FAK activation increased glycolytic metabolism (aerobic 217 
glycolysis), which substituted mitochondrial respiration 39. Consequently, ROCK inhibition 218 
could lead to down regulated FAK activity followed by suppressed mTORC1 signaling and a 219 
decreased proliferative (glycolytic) metabolism, which is in agreement with our results, as early 220 
as 12h.   221 
The serine-glycine-threonine pathway is directly connected to one-carbon metabolism, 222 
which is the folate and methionine cycle, as independent modules. One-carbon metabolism 223 
cycles carbon units, amino acids, to maintain redox balance and promote biosynthesis. Folate 224 
cycle activation is a sign of nucleic acid biosynthesis 40, among others. Studies in cancer 225 
metabolism have suggested that pathway activation is correlated with proliferation of cells 41,42. 226 
Serine biosynthesis and glycine metabolism promote tumorigenesis 42. Our results show that 227 
the serine-glycine-threonine pathway is down-regulated following 12h and 24h exposure and 228 
up-regulated after 48h exposure for both hESCs and hiPSCs (Figure 3). Overall, it is clear that 229 
the cells lose their highly proliferative physiology after the exposure to ROCK inhibitor and 230 
the dissociation into single cells as indicated by their metabolic profiles and the metabolic 231 
pathways affected. Their metabolic physiology never returned to the initial condition. 232 
Metabolic transitions following 48h exposure to ROCK inhibitor were similar for both 233 
hESCs and hiPSCs. In contrast, 96h exposure resulted in divergent metabolism for the two cell 234 
types. In hESCs metabolism increased; in contrast, hiPSCs had decreased metabolic activity. 235 
hESCs and hiPSCs share similar but not identical metabolism 26. This fact could explain why 236 
the same manipulation (i.e. dissociation of colonies and exposure to Y-27632) could cause 237 
different effect(s), especially when the treatment is prolonged, as was observed following 96h 238 
exposure ROCK inhibitor. Both hESCs and hiPSCs reduced their metabolic activity trying to 239 
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adapt to the new environment, something which is clear from the12h and 24h metabolic 240 
profiles. After 48h exposure, the cells appear to finally adapt to the new environment and 241 
increase their metabolic activity again, assuming a more proliferative metabolism. The two cell 242 
types follow discrete directions afterwards. Moreover, even if gene and protein expression of 243 
pluripotency markers remained high following 96h exposure to ROCK inhibitor, a small but 244 
significant decrease in the percentage of pluripotent cells was observed. This could explain the 245 
divergent effects on the metabolism between the two types of cells after 96h of exposure, where 246 
hESCs increase their metabolite pools further while hiPSCs show a decrease in their metabolic 247 
activity when compared to 48h exposure. It becomes clear that hESCs respond differentially to 248 
the prolonged exposure to ROCK inhibitor and single cultivation than hiPSCs.  249 
Both hESCs and hiPSCs encounter a critical point in culture at 24h of exposure, as 250 
indicated by the metabolic change commensurate with reduction in mTORC1. It has been 251 
shown that metabolism plays a significant role in defining human pluripotent stem cell fate, 252 
mostly by affecting the epigenome, in an irreversible way following a critical point 5,43,44. 253 
Increased mTORC1 expression favors growth metabolism, i.e. increased glycolysis and 254 
glutaminolysis, whereas the opposite effect is expected when mTORC1 is not expressed. 255 
Interestingly, tp53 expression is also increased at 96h compared to 24h in hiPSCs – this may 256 
represent an attempt of cells to control proliferative activity. High mTORC1 expression 45 257 
induces tp53, as the two proteins counter-balance each other 46,47, with mTORC1 favoring 258 
growth when environmental conditions (nutrients, O2, etc.) are appropriate 
48, while tp53 259 
suppresses growth and proliferation when necessary 49-51. ROCK inhibition blocks the pathway 260 
of myosin II to caspase-induced apoptosis 52. In hESCs, caspase-3 expression decreased after 261 
96h exposure but not at 48h exposure, coincident with activation of the glycolysis pathway at 262 
96h with respect to production of glycerolipids and phospholipids, consistent with previous 263 
work that showed that caspase-driven apoptosis is metabolically demanding 34.  264 
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ROS/RNS and catalase expression analyses indicate a positive correlation between 265 
proliferative metabolism and oxidative stress. The decrease in ROS/RNS levels in hESCs is 266 
followed by a decrease in mTORC1 expression, while the increase in ROS/RNS levels and 267 
catalase expression at 96h at hiPSCs cultures correlates with a more proliferative metabolism 268 
and increased mTORC1 expression. Our results are in agreement with the literature. 269 
Specifically, a positive relationship between pluripotency and hPSC maintenance with 270 
proliferative metabolism and reduction of ROS 53 has already been established. Similarly, 271 
ROCK inhibition has been linked to down-regulation of oxidative stress54.  272 
Metabolism represents the cellular function that is most sensitive to even small 273 
environmental disturbances; GC-MS metabolomics has already been proven sensitive enough 274 
to detect changes in the physiology of cell cultures compared to gene and protein expression 275 
55, something of great value in the fields of stem cell biology and cell culture engineering in 276 
terms of monitoring and bioprocess optimization. Ultimately, metabolomics could be used as 277 
a release assay for verifying both product (cells) and bioprocess quality. 278 
In conclusion, exposure to ROCK inhibitor altered cellular metabolism whereas gene 279 
and protein expression of pluripotency markers remained unaffected; as early as 12h exposure 280 
to ROCK inhibitor resulted in the metabolism of both hESCs and hiPSCs being different than 281 
that of unexposed cells. Generally, hPSC metabolism decreased for the first 24h of exposure 282 
and then increased again at 48h exposure for both hESCs and hiPSCs, with completely 283 
disparate metabolic pathways followed following 96h exposure. The observed metabolic 284 
changes correlated well with similar changes in mTORC1 expression, a principal metabolic 285 
regulator, yet were independent of tp53 and caspase-3 expression levels. Our findings indicate 286 
that metabolomics is essential in deciphering changes of physiology and is an invaluable tool 287 
in the field of stem cell bioprocessing as it can be used to identify optimal physiological 288 
transitions and result in robust cultivation processes. 289 
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Methods 290 
 291 
Cell Cultures 292 
The pluripotent stem cell lines, hESCs (WA09) and hiPSCs (MR90-1) from WiCell 293 
Research Institute, WI, USA were used at passages 29 to 33. Cells were cultured in mTeSR1 294 
(STEMCELL Technologies Canada Inc., Vancouver, BC) in Matrigel Matrix (Corning, NY, 295 
US) as recommended by the manufacturer. The hESCs and hiPSCs were either treated with 296 
10μM of Y-27632 ROCK inhibitor or not. Samples were collected at different time-points, 0-297 
untreated, 12, 24, 48, 96 hours (h) and tested over the expression of pluripotency markers 298 
(Figure 1A). The earliest time point that meaningful analysis could be performed is 12h as the 299 
single cells need sufficient time to attach to the culture surface. Samples treated with ROCK 300 
inhibitor (Y-27632) where cultured in mTeSR1 with 10μΜ Y-27632 (dihydrochloride - Tocris 301 
Bioscience, Bristol, UK) for 2 hours. Thereafter, cells were detached with the use of Accutase 302 
(StemPro - Thermo Fisher Scientific, MA, USA), colonies were dissociated into single 303 
cells by pipetting 22-24, seeded at 30-40*104 cells/cm2 density on Matrigel and 304 
cultured in mTeSR1 with 10μΜ Y-27632 up to 96h. Samples from three independent 305 
experiments (N = 3) were collected.  306 
 307 
Quantitative PCR 308 
Total RNA from hESCs and hiPSCs was extracted using the RNeasy mini kit (QIAGEN 309 
Sciences, MD, USA).  The primers used were: sox2 F-5′-GCCGAGTGGAAACTTTTGTCG-310 
3′, R-5′-GCAGCGTGTACTTATCCTTCTT-3′ 56, oct4 F-5′-311 
GTTGATCCTCGGACCTGGCTA-3′ R-5′-GGTTGCCTCTCACTCGGTTCT-3′ 56, nanog F-312 
5′-GTCTTCTGCTGAGATGCCTCACA-3′ R-5′-CTTCTGCGTCACACCATTGCTAT-3′ 56, 313 
caspase3 F-5'-AATTGTGGAATTGATGCGTGATG-3' R-5'-314 
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CTACAACGATCCCCTCTGAAAAA-3' 57, tp53 F-5'-CCAGGGCAGCTACGGTTTC-3' R-315 
5'-CTCCGTCATGTGCTGTGACTG-3' 58, mtorc1 F-5'-316 
CTGGGACTCAAATGTGTGCAGTTC-3' R-5'-GAACAATAGGGTGAATGATCCGGG-3' 317 
59, gapdh F-5’-ACCACAGTCCATGCCATCAC-3’ R-5’-TCCACCACCCTGTTGCTGTA-3’ 318 
59, F-5′-CCTTCTGGCACAGCACGTTG-3′ R-5′-TAAGACGGCATCTCGCTCCT-3′ gcs60, 319 
F-5′-CCTCAAGTACGTCCGACCTG-3 R-5′-CAATGTCGTTGCGGCACACC-3′ gpx-160, 320 
F-5′-GCAGATACCTGTGAACTGTC-3′ R-5′-GTAGAATGTCCGCACCTGAG-3′ 321 
catalase60. One-step cDNA synthesis and PCR analysis was applied, using the KAPA SYBR 322 
FAST ABI Prism One-Step qRT-PCR kit (Kapa Biosystems, Inc.  MA, US). Relative 323 
quantification was obtained measuring SYBR Green I fluorescence (ROX reference dye) with 324 
the StepOnePlus (Applied Biosystems - Thermo Fisher Scientific, MA, USA) qPCR 325 
instrument. Per reaction, 1 ng of RNA was used. 326 
 327 
Metabolite profiling 328 
Cells were washed twice with PBS before cold methanol (-40oC) was added to culture 329 
plates (6-well - Corning, NY, US). At least 106 cells were extracted from each replicate-sample 330 
of hPSCs using ribitol (1 mg/1x106 cells) as an internal standard, as previously described 55. 331 
The process of methoximation (50 μL of 20 mg methoxyamine hydrochloride/mL pyridine) 332 
and MSTFA (100 μL of N-methyl-trimethylsilyl-trifluoroacetamide) derivatization turned the 333 
dried polar extracts into their (MeOx) TMS-derivatives 61,62. Metabolic profiles were obtained 334 
using QP2010 Ultra GC-MS and GCMSsolution software Ver.4.11 (Shimadzu Corp., Kyoto, 335 
Japan). The raw metabolomics dataset was comprised of 84 peaks of known chemical category 336 
metabolites. From each independent sample, three experimental replicates (n = 3) were created. 337 
The relative peak areas of all detected peaks (RPAs) were estimated from their normalization 338 
with the 103 marker ion peak area of the internal standard ribitol. Data normalization and 339 
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filtering are applied before incorporation into the final dataset table 61,62. Cumulative (effective) 340 
peak areas were calculated using weight coefficients of the hESCs 0h-untreated cells. All 341 
analyses applied on the acquired metabolic profiles were based on standardized values of the 342 
metabolite relative peak areas 55.  343 
 344 
Flow Cytometry 345 
Cells were assessed for both intracellular and extracellular markers of pluripotency. 346 
After fixation and permeabilization for intracellular marker expression, cells were stained with 347 
–phycoerythrin (PE)-conjugated Mouse anti-Human Nanog (Clone N31-355), PerCP-Cy5.5-348 
conjugated Mouse anti-Oct3/4 (Clone 40/Oct3) and Alexa Fluor 647-conjugated Mouse anti-349 
Sox2 (Clone 245610) (BD Human Pluripotent Stem Cell Transcription Factor Analysis Kit). 350 
For extracellular marker expression, cells were stained with phycoerythrin (PE)-conjugated -351 
Rat anti-SSEA-3 (Clone MC631) and Alexa Fluor 647-conjugated Mouse anti-Human TRA-352 
1-81 (Clone TRA-1-81) (BD StemFlow Human Pluripotent Stem Cells Sorting and Analysis 353 
Kit). Isotypes controls used were phycoerythrin (PE)-conjugated Rat IgM (R4-22), Alexa Fluor 354 
647-conjugated Mouse IgM (G155-228), phycoerythrin (PE)-conjugated Mouse IgG (MOPC-355 
21), PerCP-Cy5.5-conjugated Mouse IgG (X40), Alexa Fluor 647-conjugated Mouse IgG2a 356 
(MOPC-173). In all cases, cells were collected with the use of Accutase and counted using a 357 
standard haemocytometer. All antibodies were used at a concentration of 20μL/sample 358 
obtained from BD Biosciences (BD Biosciences, San Jose, CA). BD LSRFortessa (BD 359 
Biosciences, San Jose, CA) was the instrument used for the analyses and 10000 events were 360 
analysed for each sample. FlowJo 10.1 (FlowJo LLC, OR, USA) software was used for the 361 
data analyses.  362 
 363 
 364 
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Statistical analyses 365 
 One-way ANOVA with Bonferroni post hoc test was used for flow cytometry and qRT-366 
PCR data comparison (N=3, n=3). The level of statistical significance was set by p<0.05. The 367 
p-values where differences were significant are clearly noted on the figures. Unsupervised 368 
Hierarchical Clustering (HCL) and Principal Component Analysis (PCA) algorithms were used 369 
as visualization methods of the differences among samples, based on their metabolic profiles 370 
(N=3, n=3). The Euclidean distance metric was used in HCL. Significance analysis of 371 
microarrays (SAM) was used to identify the metabolites, whose concentration was significantly 372 
higher or lower in a set of metabolic profiles compared to another, with false discovery rate 373 
(FDR) at zero 63. TM4 MeV v4.9.1 (Dana-Farber Cancer Institute, MA) was used for the 374 
multivariate64  and Origin2016 (OriginLab Corporation, MA) for univariate statistical analyses.  375 
 376 
Immunocytochemistry 377 
Sox2 and Oct4 protein expression was assessed using immunofluorescence. Cells were 378 
washed with PBS and fixed with 4% (w/v) paraformaldehyde solution in PBS (Sigma-Aldrich, 379 
UK) and subsequently blocked with a PBS solution of 10% (v/v) normal donkey serum, 0.1% 380 
(w/v) Triton X-100 and 1% (w/v) BSA (Sigma-Aldrich, UK) for 45min at room temperature 381 
in order to avoid non-specific antibody binding. After blocking, the cells were incubated for 3h 382 
with conjugated antibodies at 1:10 dilution (NL557 PE-conjugated Goat Anti-Human SOX2, 383 
NL637 Alexa Fluor 647-conjugated Goat Anti-Human Oct-4) (R&D Systems Inc, MN) at room 384 
temperature and counterstained with DAPI for 5 min. Images were taken with a BX-51 385 
Olympus microscope (Olympus, UK). 386 
 387 
 388 
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ROS/RNS assay 389 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) levels were 390 
evaluted with the use of quenched fluorogenic probe dichlorodihydrofluorescin (DCFH-391 
DiOxyQ; OxiSelect, Cell Biolabs, CA). Cells were resuspendend at a cell density of 1 x 107 392 
cells/mL in PBS and lysed with 1% (w/v) Triton X-100 solution and spinned at 10000g for 393 
5min to remove insoluble particles. They were assayed according to the manufacturer’s 394 
instructions. 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
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 595 
Figure Legends 596 
 597 
Figure 1: Assessment of pluripotency phenotype by conventional markers following exposure 598 
to ROCK inhibitor. (a) Experimental design. hPSCs were pre-treated with 10 μΜ Y-27236 599 
ROCK inhibitor for 1-2 hours. Then, colonies were dissociated into single cells and exposed 600 
to 10 μΜ Y-27236 ROCK inhibitor. Samples were collected at five time-points: 0h were 601 
untreated with cells remained in colonies whereas single cells were sampled at all other time-602 
points (12h, 24h, 48h and 96h). (b) hPSC cell phenotype by flow cytometry and qRT-PCR was 603 
maintained for at least 48 hours following exposure to ROCK inhibitor, with reduction in 604 
stemness phenotype noted by 96 hours. *p<0.05 605 
 606 
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Figure 2: Principal Component Analysis (PCA) and Hierarchical Clustering (HCl). (a) PCA 607 
graphs show the difference of 0h-untreated profiles of both hESCs and hiPSCs compared with 608 
that of the other time-points. Interestingly, profiles of the 0h (green) for both hPSCs are 609 
grouped in the left side of the graphs. It can also be observed that 48h and 96h profiles are 610 
grouped together and seems closer compared to the highest spreading of 12h and 24h profiles.  611 
ROCK inhibitor changed metabolic physiology compared with that of the 0h untreated cells. 612 
(b) HCL and heatmaps indicate that clustering of metabolic profiles is similar for both types of 613 
hPSCs and dependent on exposure time to ROCK inhibitor. Metabolism over time appear 614 
similar for both cell types throughout the experimental process, though not identical. 0h-615 
untreated profiles form a discrete cluster in both types of cells. (Distance Metric: Euclidean on 616 
standardized relative peak areas – stRPAs) 617 
 618 
Figure 3: Network representation of significant metabolic changes over time. Significance 619 
analysis of microarrays (SAM) was applied between time-points. The metabolic transitions are 620 
similar up to 48h. 48h to 96h transition is different between hESCs and hiPSCs. Glycolysis, 621 
glutaminolysis and amino acid pools are up-regulated at 0h, they reach their lower level at 24h 622 
and they increase their activity again at 48h. At 96h the metabolite pools are increasing for the 623 
hESCs and decreasing for the hiPSCs. 624 
 625 
Figure 4: Caspase 3 expression over time in hESCs. (a) Caspase 3 expression is significantly 626 
reduced at 96h compared with that at 48h, (p<0.05) (expressions always relative to 0h). (b) 627 
This effect at 96h is highlighted by the increased metabolite pools, as expected when cells 628 
commit to apoptosis, a metabolically-demanding process.  629 
 630 
27 
 
Figure 5: Expression of mTORC1 and tp53 in hESCs exposed to ROCK inhibitor and on-631 
network representation. (a) mTORC1 expression is significantly reduced at 24h and 96h 632 
compared with that at 0h in hESCs (p<0.05), whereas expression of tp53 is unchanged 633 
throughout culture (expressions always relative to 0h). (b) Reduction of mTORC1 expression 634 
correlated with significant decreases in the concentration of metabolite pools at 24h compared 635 
to 0h and a further decrease at 96h. The comparisons applied were chosen accordingly to the 636 
significant changes on gene expression. 637 
 638 
Figure 6: Expression of mTORC1 and tp53 in hiPSCs exposed to ROCK inhibitor and on-639 
network representation. (a) mTORC1 is less expressed at 24h compared with that at 0h; 640 
expression increases again at 96h (p<0.05). Expression of tp53 is also increased at 96h 641 
compared with that at 24h (p<0.05) (expressions always relative to 0h). (b) These changes in 642 
mTORC1 and tp53 expression are reflected in the metabolic transitions, wherein metabolite 643 
pools decreased at 24h and increased again at 96h. The comparisons applied were chosen 644 
accordingly to the significant changes on gene expression.  645 
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